Last update May 1, 2016
A macrolide antibiotic that is approved for pediatric use. Frequently used in young infants
At latest update no published data on excretion into breast milk were found.
It has higher molecular weight and shorter half-life elimination span than other macrolide antibiotics like azithromycin and claritormycin that are excreted into breast milk in negligible amount.
Until more published information about this drug regarding breastfeeding appears, it may be preferable a known and safer alternative, especially during the neonatal period and in cases of prematurity.
Early exposure to macrolide antibiotics (especially erythromycin) has been linked to hypertrophic pyloric stenosis, even through breast milk, being it a reason to avoid them during the first month of breastfeeding.
Take into account the possible negative results of bacterial cultures among febrile infants when their mothers are on antibiotics, as well as the possibility of gastroenteritis by altering the intestinal flora.
Suggestions made at e-lactancia are done by APILAM team, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM